Gilead Sciences (GILD) Tops Q3 EPS by 38c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/23/2026
- S&P 500, Nasdaq close lower, dragged by Alphabet and megacap tech; focus on Iran
- Oil settles down more 3% after US-Iran talks signal easing supply risks
- Micron surges 5.5% on blockbuster Anthropic AI deal ahead of earnings
- Alan Greenspan, influential former Federal Reserve chair, dies at 100
- Buy gold stocks as valuations are cheap amid macro tension: BofA
- Exclusive-China robot-hand-building unicorn Linkerbot targets $6 billion valuation
- Spain's ex-transport minister sentenced to 24 years for corruption
- China, US, UAE police arrest 276 telecom fraud suspects in Dubai
- Li Auto Inc. (LI) Breaks Ground on Chips R&D and Production Base
- 'Equal and opposite': BTIG's Krinsky sees sharp reversal ahead for chip stocks
Gilead Sciences Announces Third Quarter 2022 Financial Results
October 27, 2022 4:01 PM EDTProduct Sales Excluding Veklury Increased 11% Year-Over-Year to $6.1 billion
Biktarvy Sales Increased 22% Year-Over-Year to $2.8 billion
Oncology Sales Increased 79% Year-Over-Year to $578 million
FOSTER CITY, Calif.--(BUSINESS WIRE)-- Gilead Sciences, Inc. (Nasdaq: GILD) announced today its results of operations for the third quarter of 2022.
Chairman and Chief Executive Officer of Gilead Sciences, Daniel ODay said: This was another very strong quarter across the business. In HIV, treatment and prevention markets continue to grow with further share gains for Biktarvy... More
